The myocardial matrix and the development and progression of ventricular remodeling

Current Cardiology Reports

Volumn 2, Issue 2, 2000, Pages 112-119

  Sackner Bernstein, Jonathan D ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

ANIMAL; BIOLOGICAL MODEL; CONGESTIVE HEART FAILURE; CYTOLOGY; HEART MUSCLE; HEART VENTRICLE REMODELING; HEMODYNAMICS; HUMAN; IMMUNOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; MODELS, CARDIOVASCULAR; MYOCARDIUM; NEUROTRANSMITTER AGENTS; VENTRICULAR REMODELING;

EID: 0034153434     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-000-0007-4     Document Type: Article

References (91)

1. Packer M: Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure. Eur Heart J 1995, 16(Suppl) F:4-6.
2. Levine TB, Francis GS, Goldsmith SR, et al. : Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 1982, 49:1659-1666.
3. Cohn JN, Levin TB, Olivari MT, et al. : Plasma norepinephrine as a guide to prognosis in patients with chronic heart failure. N Engl J Med 1984, 311:819-823.
4. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987, 316:1429-1435.
5. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302.
6. Pfeffer M, Braunwald E, Moye L, et al. : Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992, 327:669-677.
7. Packer M, Bristow M, Cohn J, et al. : The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996, 334:1349-1355.
8. The International Steering Committee: Rationale, design, and organization of the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF). Am J Cardiol 1997, 80:54J-58J.
9. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353:9-13.
10. Rumberger JA, Behrenbeck T, Breen JR, et al. : Nonparallel changes in global left ventricular chamber volume and muscle mass during the first year after transmural myocardial infarction in humans. J Am Coll Cardiol 1993, 21:673-682.
11. Tyagi SC: Proteinases and myocardial extracellular matrix turnover. Mol Cell Biochem 1997, 168:1-12.
12. Brilla CG, Zhou G, Matsubara L, Weber KT: Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994, 26:809-820.
13. Simms H, D'Amico R: Regulation of polymorphonuclear leukocyte cytokine receptor expression: the role of altered oxygen tensions and matrix proteins. J Immunol 1996, 157:3605-3616.
14. Tyagi SC, Lewis K, Pikes D, et al. : Stretch-induced membrane type matrix metalloproteinase and tissue plasminogen activator in cardiac fibroblast cells. J Cell Physiol 1998, 176:374-382.
15. Sabbah HN, Sharov VG: Apoptosis in heart failure. Prog Cardiovasc Dis 1998, 40:549-562.
16. Cheng W, Li B, Kajstura J, et al. : Stretch-induced programmed myocyte cell death. J Clin Invest 1995, 96:2247-2259.
17. Pulkki KJ: Cytokines and cardiomyocyte death. Ann Med 1997, 29:339-343.
18. Desch CE, Magorien RD, Triffon DW, et al. : Development of pharmacodynamic tolerance to prozosin in congestive heart failure. Am J Cardiol 1979, 44:1178-1182.
19. Bishop J, Lindahl G: Regulation of cardiovascular collagen synthesis by mechanical load. Cardiovascular Research 1999, 42:27-44.
20. Eghbali M: Cardiac fibroblasts: function, regulation of gene expression, and phenotypic modulation. Basic Res Cardiol 1992, 87(suppl 2):183-189.
21. Butt RP, Laurent GJ, Bishop JE: Collagen production and replication by cardiac fibroblasts is enhanced in response to diverse classes of growth factors. Eur J Cell Biol 1995, 68:330-335.
22. Fisher SA, Absher M: Norepinephrine and ANG II stimulate secretion of TGF-beta by neonatal rat cardiac fibroblasts in vitro. Am J Physiol 1995, 268:C910-C917.
23. Li, Feldman, Tiernan : Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 1998, 98:1728-1734.
24. Shimizu N, Yoshiyama M, Takeuchi K, et al. : Doppler echocardiographic assessment and cardiac gene expression analysis of the left ventricle in myocardial infarcted rats. Jpn Circ J 1998, 62:436-442.
25. Armstrong PW, Moe GW, Howard RJ, et al. : Structural remodelling in heart failure: gelatinase induction. Can J Cardiol 1994, 10:214-220.
26. Tyagi SC, Kumar S, Voelker DJ, et al. : Differential gene expression of extracellular matrix components in dilated cardiomyopathy. J Cell Biochem 1996, 63:185-198.
27. Bhambi B, Eghbali M: Effect of norepinephrine on myocardial collagen gene expression and response of cardiac fibroblasts after norepinephrine treatment. Am J Pathol 1991, 139:1131-1142.
28. Kostuk WJ, Kazamias TM, Gander MP, et al. : Left ventricular size after acute myocardial infarction. Serial changes and their prognostic significance. Circulation 1973, 47:1174-1179.
29. Lee TH, Hamilton MA, Stevenson LW, et al. : Impact of left ventricular cavity size on survival in advanced heart failure. Am J Cardiol 1993, 72:672-676.
30. Olivetti G, Capasso JM, Sonnenblick EH, Anversa P: Side-toside slippage of myocytes participates in ventricular wall remodeling acutely after myocardial infarction in rats. Circ Res 1990, 67:23-34.
31. Gerdes A, Kellerman S, Moore J, et al. : Structural remodeling of cardiac myocytes in patients with ischemic cardiomyopathy. Circulation 1992, 86:426-430.
32. Nicoletti A, Heudes D, Mandet C, et al. : Inflammatory cells and myocardial fibrosis: spatial and temporal distribution in renovascular hypertensive rats. Cardiovasc Res 1996, 32:1096-1107.
33. Yue P, Massie BM, Simpson PC, Long CS: Cytokine expression increases in nonmyocytes from rats with postinfarction heart failure. Am J Physiol 1998, 275:H250-H258.
34. Ono K, Matsumori A, Shioi T, et al. : Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation 1998, 98:149-156.
35. Katwa LC, Campbell SE, Tyagi SC, et al. : Cultured myofibroblasts generate angiotensin peptides de novo. J Mol Cell Cardiol 1997, 29:1375-1386.
36. Harada M, Itoh H, Nakagawa O, et al. : Significance of ventricular myocytes and nonmyocytes interaction during cardiocyte hypertrophy: evidence for endothelin-1 as a paracrine hypertrophic factor from cardiac nonmyocytes. Circulation 1997, 96:3737-3744.
37. Chapleau MW, Hajduczok G, Abboud FM: Suppression of baroreceptor discharge by endothelin at high carotid sinus pressure. Am J Physiol 1992, 263:R103-R108.
38. Wang W: Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension 1994, 24:571-575.
39. Gray MO, Long CS, Kalinyak JE, et al. : Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. Cardiovasc Res 1998, 40:352-363.
40. Bozkurt B, Kribbs SB, Clubb FJ, Jr, et al. : Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998, 97:1382-1391.
41. Kubota T, McTiernan CF, Frye CS, et al. : Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 1997, 81:627-635.
42. Gwechenberger M, Mendoza LH, Youker KA, et al. : Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation 1999, 99:546-551.
43. Birks EJ, Yacoub MH: The role of nitric oxide and cytokines in heart failure. Coron Artery Dis 1997, 8:389-402.
44. Aitken K, Nakamura H, Dawood F, et al. : The pattern of tissue cytokine expression in murine models of myocardial infarction [abstract]. J Am Coll Cardiol 1999, 33:169A.
45. Hosenpud J, Campbell S, Pan G: Indirect inhibition of myocyte RNA and protein synthesis by interleukin-1. J Mol Cell Cardiol 1990, 22:213-225.
46. Shindo T, Ikeda U, Ohkawa F, et al. : Nitric oxide synthesis in cardiac myocytes and fibroblasts by inflammatory cytokines. Cardiovasc Res 1995, 29:813-819.
47. Palmer JN, Hartogensis WE, Patten M, et al. : Interleukin-1 beta induces cardiac myocyte growth but inhibits cardiac fibroblast proliferation in culture. J Clin Invest 1995, 95:2555-2564.
48. Calderone A, Thaik CM, Takahashi N, et al. : Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growthpromoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 1998, 101:812-818.
49. Finkel MS, Oddis CV, Jacob TD, et al. : inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992, 257:387-389.
50. Kanwar S, Kubes P: Ischemia/reperfusion-induced granulocyte influx is a multistep process mediated by mast cells. Microcirculation 1994, 1:175-182.
51. Frangogiannis NG, Lindsey ML, Michael LH, et al. : Resident cardiac mast cells degranulate and release preformed TNF-alpha, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion. Circulation 1998, 98:699-710.
52. Kapadia SR, Oral H, Lee J, et al. : Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. Circ Res 1997, 81:187-195.
53. Yamada T, Horiuchi M, Dzau VJ: Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci U S A 1996, 93:156-160.
54. Maulik N, Yoshida T, Das DK: Oxidative stress developed during the reperfusion of ischemic myocardium induces apoptosis. Free Radic Biol Med 1998, 24:869-875.
55. Bialik S, Geenen DL, Sasson IE, et al. : Myocyte apoptosis during acute myocardial infarction in the mouse localizes to hypoxic regions but occurs independently of p53. J Clin Invest 1997, 100:1363-1372.
56. Host N, Jensen L, Bendixen P, et al. : The aminoterminal propeptide of type III procollagen provides new infomration on prognosis after acute myocardial infarction. Am J Cardiol 1995, 76:869-873.
57. Baghelai K, Marktanner R, Dattilo JB, et al. : Decreased expression of tissue inhibitor of metalloproteinase 1 in stunned myocardium. J Surg Res 1998, 77:35-39.
58. Zhao M, Zhang H, Robinson T, et al. : Profound structural alterations of the extracellular collagen matrix in postischemic dysfunctional ("stunned") but viable myocardium. J Am Coll Cardiol 1987, 10:1322-1334.
59. Kukielka GL, Smith CW, Manning AM, et al. : Induction of interleukin-6 synthesis in the myocardium. Potential role in postreperfusion inflammatory injury. Circulation 1995, 92:1866-1875.
60. Weber KT, Janicki JS, Shroff SG, et al. : Collagen remodeling of the pressure-overloaded, hypertrophied nonhuman primate myocardium. Circ Res 1988, 62:757-765.
61. Pietersma A, de Jong N, Sluiter W, Koster JF: Studies on the interaction of leucocytes and the myocardial vasculature. I. Effect of hypoxia on the adherence of blood granulocytes. Mol Cell Biochem 1992, 116:197-202.
62. Tyagi SC, Kumar S, Borders S: Reduction-oxidation (redox) state regulation of extracellular matrix metalloproteinases and tissue inhibitors in cardiac normal and transformed fibroblast cells. J Cell Biochem 1996, 61:139-151.
63. Mann DL, Kent RL, Parsons B, Cooper GT: Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992, 85:790-804.
64. Kaddoura S, Firth J, Noheler K, et al. : Endothelin-1 in involved in norepinephrine-induces ventricular hypertrophy in vivo: acute effects of bosentan, an orally active, mixed endothelin ETA nd ETB receptor antagonist. Circulation 1996, 93:2068-2079.
65. Brilla CG, Scheer C, Rupp H: Angiotensin II and intracellular calcium of adult cardiac fibroblasts. J Mol Cell Cardiol 1998, 30:1237-1246.
66. Lown B, Verrier R: Neural activity and ventricualr fibrillation. N Engl J Med 1976, 294:1165-1170.
67. Booz GW, Baker KM: Molecular signalling mechanisms controlling growth and function of cardiac fibroblasts. Cardiovasc Res 1995, 30:537-543.
68. Takizawa T, Gu M, Chobanian AV, Brecher P: Effect of nitric oxide on DNA replication induced by angiotensin II in rat cardiac fibroblasts. Hypertension 1997, 30:1035-1040.
69. Re R: The myocardial intracellular renin-angiotensin system. Am J Cardiol 1987, 59:56A-58A.
70. Kim NN, Villegas S, Summerour SR, Villarreal FJ: Regulation of cardiac fibroblast extracellular matrix production by bradykinin and nitric oxide. J Mol Cell Cardiol 1999, 31:457-466.
71. MacFadyen RJ, Barr CS, Struthers AD: Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997, 35:30-34.
72. Pitt B, Zannad F, Remme WJ, et al. : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators [see comments]. N Engl J Med 1999, 341:709-717.
73. Hall SA, Cigarroa CG, Marcoux L, et al. : Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with betaadrenergic blockade. J Am Coll Cardiol 1995, 25:1154-1161.
74. Bristow MR, Ginsburg R, Umans V, et al. : Beta 1-and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 1986, 59:297-309.
75. Iizuka K, Sano H, Kawaguchi H, Kitabatake A: Transforming growth factor beta-1 modulates the number of betaadrenergic receptors in cardiac fibroblasts. J Mol Cell Cardiol 1994, 26:435-440.
76. Landmann R: Beta-adrenergic receptors in human leukocyte subpopulations. Eur J Clin Invest 1992, 22(suppl 1):30-36.
77. Sugden PH, Fuller SJ, Mynett JR, et al. : Stimulation of adult rat ventricular myocyte protein synthesis and phosphoinositide hydrolysis by the endothelins. Biochim Biophys Acta 1993, 1175:327-332.
78. Fraccarollo D, Hu K, Galuppo P, et al. : Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardilal infarction. Circulation 1997, 96:3963-3973.
79. Waagstein F, Mobini R, Andersson B, et al. : Moxonidine attenuates trasmyocardial norepinephrine concentration gradient and total body norepinephrine spillover in congestive heart failure [abstract]. Euro J Cardiol 1998, 22:1056.
80. Cohn JN, Archibald DG, Ziesche S, et al. : Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986, 314:1547-1552.
81. Peng M, Li Y, Luo Z, et al. : Alpha2-adrenergic agonists selectively activate extracellular signal-regulated kinases in Muller cells in vivo. Invest Ophthalmol Vis Sci 1998, 39:1721-1726.
82. Bamberger CM, Monig H, Mill G, et al. : Growth hormone secretion in response to the new centrally acting antihypertensive agent moxonidine in normal human subjects: comparison to clonidine and GHRH. Exp Clin Endocrinol Diabetes 1995, 103:205-208.
83. Ricci A, Bronzetti E, Conterno A, et al. : alpha1-adrenergic receptor subtypes in human peripheral blood lymphocytes. Hypertension 1999, 33:708-712.
84. Matsumori A, Shioi T, Yamada T, et al. : Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation 1994, 89:955-958.
85. Cohn JN, Goldstein SO, Greenberg BH, et al. : A dosedependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med 1998, 339:1810-1816.
86. Bozkurt B, Torre-Amione G, Soran O, et al. : Results of a multidose phase I trial with enbrel (etanercept, p75 TNF receptor fusion protein) in patients with heart failure. J Am Coll Cardiol 1999, 1110-1114.
87. Rohde LE, Ducharme A, Arroyo LH, et al. : Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 1999, 99:3063-3070.
88. Spinale FG, Coker ML, Krombach SR, et al. : Matrix metalloproteinase inhibition during the development of congestive heart failure : effects on left ventricular dimensions and function. Circ Res 1999, 85:364-376.
89. Murohara T, Guo JP, Lefer AM: Cardioprotection by a novel recombinant serine protease inhibitor in myocardial ischemia and reperfusion injury. J Pharmacol Exp Ther 1995, 274:1246-1253.
90. Shimai S, Takano T, Seino Y, et al. : Role of PMN elastase on ischemic myocardial injury in evolving myocardial infarction: correlation with clinical parameters and intervention by protease inhibitor ulinastatin. Jpn Circ J 1989, 53:1144-1151.
91. Shibata T, Yamamoto F, Suehiro S, Kinoshita H: Effects of protease inhibitors on postischemic recovery of the heart. Cardiovasc Drugs Ther 1997, 11:547-556.